Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.95 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinazoline SCHEMBL19877280 | 1.00 | EGFR (0.95) | EGFRPIK3CDPIK3CAALDH1A1CYP1A2 | |
| Quinazoline SCHEMBL22833783 | 0.98 | EGFR (1.00) | EGFRPIK3CDPIK3CAALDH1A1CYP1A2 | |
| Quinazoline SCHEMBL29490398 | 0.98 | EGFR (1.00) | EGFRPIK3CDPIK3CAALDH1A1CYP1A2 | |
| Quinazoline SCHEMBL5920 | 0.98 | EGFR (1.00) | EGFRPIK3CDPIK3CAALDH1A1CYP1A2 | |
| Quinazoline SCHEMBL29356169 | 0.98 | EGFR (1.00) | EGFRPIK3CDPIK3CAALDH1A1CYP1A2 | |
| Quinazoline SCHEMBL5579413 | 0.95 | EGFR (0.95) | EGFRPIK3CDPIK3CAALDH1A1CYP1A2 | |
| Quinazoline SCHEMBL4487630 | 0.95 | EGFR (0.95) | EGFRPIK3CDPIK3CAALDH1A1CYP1A2 | |
| Quinazoline SCHEMBL1119374 | 0.95 | EGFR (0.95) | EGFRPIK3CDPIK3CAALDH1A1CYP1A2 | |
| Quinazoline SCHEMBL21055790 | 0.95 | EGFR (0.95) | EGFRPIK3CDPIK3CAALDH1A1CYP1A2 | |
| Quinazoline SCHEMBL167076 | 0.95 | EGFR (0.95) | EGFRPIK3CDPIK3CAALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121226382-A | Pyrrole quinazoline diamine derivative, and preparation method and application thereof | 井冈山大学 | 2025-12-30 | — | — | CN | disclosed |
| CN-121226382-A | Pyrrole quinazoline diamine derivative, and preparation method and application thereof | 井冈山大学 | 2025-12-30 | — | — | CN | disclosed |
| CN-118271249-A | Diazonium transfer reagent and preparation method and application thereof | 中国科学院上海有机化学研究所 | 2024-07-02 | — | — | CN | disclosed |
| CN-115353507-B | Biphenyl pyrazine quinazoline diamine, synthesis, activity and application thereof | 首都医科大学 | 2023-10-20 | — | — | CN | disclosed |
| CN-115353507-B | Biphenyl pyrazine quinazoline diamine, synthesis, activity and application thereof | 首都医科大学 | 2023-10-20 | — | — | CN | disclosed |
| CN-115353507-B | Biphenyl pyrazine quinazoline diamine, synthesis, activity and application thereof | 首都医科大学 | 2023-10-20 | — | — | CN | disclosed |
| CN-115353507-A | Biphenyl pyrazine quinazoline diamine, synthesis, activity and application thereof | 首都医科大学 | 2022-11-18 | — | — | CN | disclosed |
| CN-115353507-A | Biphenyl pyrazine quinazoline diamine, synthesis, activity and application thereof | 首都医科大学 | 2022-11-18 | — | — | CN | disclosed |
| CN-115353507-A | Biphenyl pyrazine quinazoline diamine, synthesis, activity and application thereof | 首都医科大学 | 2022-11-18 | — | — | CN | disclosed |
| CN-110627731-A | 4-aminoquinazoline-linked acrylamide compound and preparation method and application thereof | 贵州大学 | 2019-12-31 | — | — | CN | disclosed |
| CN-109432140-A | A kind of synergy system of the plant extracts with DPP-4 inhibitory activity | 黄泳华 | 2019-03-08 | — | — | CN | disclosed |
| US-20100317607-A1 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2010-12-16 | — | — | US | disclosed |
| CN-101784276-A | Use of compounds for the preparation of antituberculosis agents | SUMMIT CORP PLC | 2010-07-21 | — | — | CN | disclosed |
| EP-2173346-A2 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | Summit Corporation Plc (GB) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009001060-A2 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | SUMMIT CORPORATION PLC (GB) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317607-A1 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | TPX2, DCXR, RRM2 | EGFR 4148/4885PIK3CD 3470/4885PIK3CA 3926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.